Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years A. Traboulsee,J. A. Cohen,A. J. Coles,D. A. S. Compston, E. J. Fox,G. Giovannoni,H. -P. Hartung, E. Havrdova, K. W. Selmaj, D. H. Margolin,K. Thangavelu, M. A. Panzara, D. L. ArnoldMULTIPLE SCLEROSIS JOURNAL（2015）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
